Abstract
Bone marrow mesenchymal stem cells (BMSCs) transplantation has attracted attention for the treatment of liver cirrhosis and end-stage liver diseases. Therefore, in this study, we evaluated the effect of different methods of BMSCs transplantation in the treatment of liver cirrhosis in rats. Seventy-two male Sprague-Dawley rats were divided into 7 groups: 10 were used to extract BMSCs, 10 were used as normal group, and the remaining 52 rats were randomly divided into five groups for testing: control group, BMSCs group, BMSCs+granulocyte colony-stimulating factor (G-CSF) group, and BMSCs+Jisheng Shenqi decoction (JSSQ) group. After the end of the intervention course, liver tissue sections of rats were subjected to hematoxylin and eosin (H&E) and Masson staining, and pathological grades were scored. Liver function [aminotransferase (ALT), aspartate aminotransferase (AST), albumin (ALB)] and hepatic fibrosis markers [hyaluronidase (HA), laminin (LN), type III procollagen (PCIII), type IV collagen (CIV)] were measured. BMSCs+JSSQ group had the best effect of reducing ALT and increasing ALB after intervention therapy (P<0.05). The reducing pathological scores and LN, PCIII, CIV of BMSCs+G-CSF group and BMSCs+JSSQ group after intervention therapy were significant, but there was no significant difference between the two groups (P>0.05). The effect of JSSQ on improving stem cell transplantation in rats with liver cirrhosis was confirmed. JSSQ combined with BMSCs could significantly improve liver function and liver pathology scores of rats with liver cirrhosis.
Highlights
Cirrhosis is a consequence of chronic liver disease characterized by replacement of liver tissue by fibrotic scar tissue as well as regenerative nodules, leading to progressive loss of liver function [1]
The results showed that the cell homogeneity was good, the positive rate of CD105+ was 88.5% (Figure 1B), the positive rate of CD44+ was 99.4% (Figure 1C), and the positive rate of CD34+ was 0.59% (Figure 1D), indicating that spindle cells were bone marrow mesenchymal stem cells (BMSCs)
BMSCs+Jisheng Shenqi decoction (JSSQ) group had the best effect of reducing ALT, which was significantly better than BMSCs+granulocyte colony-stimulating factor (G-CSF) group (Po0.05)
Summary
Cirrhosis is a consequence of chronic liver disease characterized by replacement of liver tissue by fibrotic scar tissue as well as regenerative nodules, leading to progressive loss of liver function [1]. Incidence of liver cirrhosis is rising worldwide with expected increases in hospital admissions and cirrhosis-related deaths [2]. The incidence of liver cirrhosis in China is increasing yearly, and about one million people die from liver cirrhosis each year, which is a serious public health problem [3]. Many studies have shown evidence that transplantation of bone marrow mesenchymal stem cells (BMSCs) can sustain liver function after liver damage [4]. The main problem affecting the efficacy of BMSCs transplantation in the treatment of liver cirrhosis is that the number of BMSCs homing to the injured liver after transplantation is insufficient. A safe and effective stem cell mobilizer is the key to improve the efficacy of BMSCs transplantation
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
